The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies

被引:72
作者
Gast, D. [1 ]
Riedle, S. [1 ]
Issa, Y. [1 ]
Pfeifer, M. [1 ]
Beckhove, P. [1 ]
Sanderson, M. P. [1 ]
Arlt, M. [2 ]
Moldenhauer, G. [1 ]
Fogel, M. [3 ]
Krueger, A. [2 ]
Altevogt, P. [1 ]
机构
[1] German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany
[2] Tech Univ Munich, Inst Expt Oncol & Therapy, Munich, Germany
[3] Kaplan Med Ctr, Dept Pathol, Rehovot, Israel
关键词
cell migration; tumor growth; signaling; therapeutic antibodies;
D O I
10.1038/sj.onc.1210747
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
L1 cell adhesion molecule (L1-CAM) is a transmembrane cell adhesion molecule involved in cell migration and axon guidance in the developing nervous system. L1 is also overexpressed in ovarian and endometrial carcinomas and is associated with a bad prognosis. In carcinoma cell lines, L1 overexpression augments cell motility, tumor growth in mice and induces expression of Erk-dependent genes. Here, we show that a mutation in the cytoplasmic portion of L1 (T1247A, S1248A) abrogates Erk activation, blocks cell migration on extracellular matrix proteins and did not augment tumor growth in non-obese diabetic/severe combined immuno-deficient mice. In cells expressing mutant L1, the induction of Erk-dependent genes such as beta 3-integrin, cathepsin-B and several transcription factors is eliminated and the invasive phenotype is abrogated. L1 antibodies showed similar effects. They prevented Erk activation and interfered with the Erk-dependent gene expression pattern. These findings provide a rationale for the mode of action of L1 antibodies and suggest that interference with L1 function could become a valuable target for therapy.
引用
收藏
页码:1281 / 1289
页数:9
相关论文
共 31 条
[1]  
Allory Y, 2005, CLIN CANCER RES, V11, P1190
[2]   Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment [J].
Arlt, MJE ;
Novak-Hofer, I ;
Gast, D ;
Gschwend, V ;
Moldenhauer, G ;
Grünberg, J ;
Honer, M ;
Schubiger, PA ;
Altevogt, P ;
Krüger, A .
CANCER RESEARCH, 2006, 66 (02) :936-943
[3]   Gene regulation in melanoma progression by the AP-2 transcription factor [J].
Bar-Eli, M .
PIGMENT CELL RESEARCH, 2001, 14 (02) :78-85
[4]   Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation [J].
Brunner, G ;
Reimbold, K ;
Meissauer, A ;
Schirrmacher, V ;
Erkell, LJ .
EXPERIMENTAL CELL RESEARCH, 1998, 239 (02) :301-310
[5]   RanBPM is an L1-interacting protein that regulates L1-mediated mitogen-activated protein kinase activation [J].
Cheng, L ;
Lemmon, S ;
Lemmon, V .
JOURNAL OF NEUROCHEMISTRY, 2005, 94 (04) :1102-1110
[6]   L1-mediated branching is regulated by two ezrin-radixin moesin (ERM)-Binding sites, the RSLE region and a novel juxtamembrane ERM-binding region [J].
Cheng, L ;
Itoh, K ;
Lemmon, V .
JOURNAL OF NEUROSCIENCE, 2005, 25 (02) :395-403
[7]   Chronic activation of ERK and neurodegenerative diseases [J].
Colucci-D'Amato, L ;
Perrone-Capano, C ;
di Porzio, U .
BIOESSAYS, 2003, 25 (11) :1085-1095
[8]   L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas [J].
Fogel, M ;
Gutwein, P ;
Mechtersheimer, S ;
Riedle, S ;
Stoeck, A ;
Smirnov, A ;
Edler, L ;
Ben-Arie, A ;
Huszar, M ;
Altevogt, P .
LANCET, 2003, 362 (9387) :869-875
[9]   L 1 adhesion molecule (CD 171) in development and progression of human malignant melanoma [J].
Fogel, M ;
Mechtersheimer, S ;
Huszar, M ;
Smirnov, A ;
Abu-Dahi, A ;
Tilgen, W ;
Reichrath, J ;
Georg, T ;
Altevogt, P ;
Gutwein, P .
CANCER LETTERS, 2003, 189 (02) :237-247
[10]   L1 augments cell migration and tumor growth but not β3 integrin expression in ovarian carcinomas [J].
Gast, D ;
Riedle, S ;
Schabath, H ;
Schlich, S ;
Schneider, A ;
Issa, Y ;
Stoeck, A ;
Fogel, M ;
Joumaa, S ;
Wenger, T ;
Herr, I ;
Gutwein, P ;
Altevogt, P .
INTERNATIONAL JOURNAL OF CANCER, 2005, 115 (04) :658-665